Catalysts for Takeda Pharmaceuticals USA Inc
143 tracked
Feb 25, 2022
approval
VYVANSE (LISDEXAMFETAMINE DIMESYLATE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Feb 25, 2022
approval
ADDERALL XR 10 (AMPHETAMINE ASPARTATE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Feb 25, 2022
approval
VYVANSE (LISDEXAMFETAMINE DIMESYLATE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Feb 15, 2022
approval
ICLUSIG (PONATINIB HYDROCHLORIDE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Jan 18, 2022
approval
LIVTENCITY (MARIBAVIR) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Nov 23, 2021
approval
LIVTENCITY (MARIBAVIR) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Nov 2, 2021
approval
VYVANSE (LISDEXAMFETAMINE DIMESYLATE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Nov 2, 2021
approval
VYVANSE (LISDEXAMFETAMINE DIMESYLATE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Aug 17, 2021
approval
ENTYVIO (VEDOLIZUMAB) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Aug 17, 2021
approval
ENTYVIO (VEDOLIZUMAB) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Jul 29, 2021
approval
VYVANSE (LISDEXAMFETAMINE DIMESYLATE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Jul 29, 2021
approval
VYVANSE (LISDEXAMFETAMINE DIMESYLATE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Dec 18, 2020
approval
ICLUSIG (PONATINIB HYDROCHLORIDE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Jul 10, 2020
approval
ICLUSIG (PONATINIB HYDROCHLORIDE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Jun 17, 2020
approval
ICLUSIG (PONATINIB HYDROCHLORIDE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Mar 31, 2020
approval
ENTYVIO (VEDOLIZUMAB) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Mar 31, 2020
approval
ENTYVIO (VEDOLIZUMAB) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Jan 10, 2020
approval
ICLUSIG (PONATINIB HYDROCHLORIDE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Jul 3, 2019
approval
ADDERALL XR 10 (AMPHETAMINE ASPARTATE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
May 7, 2019
approval
ENTYVIO (VEDOLIZUMAB) — FDA approval
Takeda Pharmaceuticals USA Inc
→
May 6, 2019
approval
ENTYVIO (VEDOLIZUMAB) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Oct 18, 2018
approval
ICLUSIG (PONATINIB HYDROCHLORIDE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Jul 16, 2018
approval
ADDERALL XR 10 (AMPHETAMINE ASPARTATE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
May 29, 2018
approval
ICLUSIG (PONATINIB HYDROCHLORIDE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Feb 16, 2018
approval
ENTYVIO (VEDOLIZUMAB) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Dec 20, 2017
approval
ICLUSIG (PONATINIB HYDROCHLORIDE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Dec 20, 2017
approval
ICLUSIG (PONATINIB HYDROCHLORIDE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Jul 31, 2017
approval
VYVANSE (LISDEXAMFETAMINE DIMESYLATE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Jul 31, 2017
approval
VYVANSE (LISDEXAMFETAMINE DIMESYLATE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
May 19, 2017
approval
VYVANSE (LISDEXAMFETAMINE DIMESYLATE) — FDA approval
Takeda Pharmaceuticals USA Inc
→